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Background: Prior studies have shown that using uterotonics to augment or induce labor before arrival at
comprehensive Emergency Obstetric and Neonatal Care (CEmONC) settings (henceforth, “outside uterotonics”) may
contribute to perinatal mortality in low- and middle-income countries. We estimate its effect on perinatal mortality
in rural Bangladesh.
Methods: Using hospital records (23986 singleton term births, Jan 1, 2009-Dec 31, 2015) from rural Bangladesh, we
use a logistic regression model to estimate the increased risk of perinatal death from uterotonics administered
outside a CEmONC facility.
Results: Among term births (≥37 weeks gestation), the risk of perinatal death adjusted for key confounders is
significantly increased among women reporting uterotonic use outside of CEmONC (OR = 3 · 0, 95 % CI = 2 · 4,3 · 7).
This increased risk is particularly high for fresh stillbirths (OR = 4 · 0, 95 % CI = 3 · 0,5 · 3) and intrapartum-related
causes of early neonatal deaths (birth asphyxia) (OR = 3 · 1, 95 % CI = 2 · 2,4 · 5).
Conclusions: In this sample, outside uterotonic use was associated with substantially increased risk of fresh
stillbirths, deaths due to birth asphyxia, and all perinatal deaths. In settings of high uterotonic use outside of
controlled settings, substantial improvement in both stillbirth and early neonatal mortality may be made by
reducing such use.
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Uterotonics can be used safely to treat disorders of labor
in a delivery hospital where the mother can be moni-
tored and complications can be treated. But in rural
Bangladesh, uterotonics are also widely available and are
often used outside of such controlled settings. We found
that more babies were born dead or died during their
first week of life if their mothers told us that they had
received uterotonics before arriving at a safe delivery
hospital. If fewer mothers received uterotonics to speed* Correspondence: louisetday@gmail.com
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Globally each year, an estimated 2 · 6 million newborns
die [1], and another 2 · 6 million babies are stillborn, half
of whom die during labour and birth [2, 3]. The vast ma-
jority (>98 %) of these deaths occur in low- and middle-
income countries [3, 4]. With other causes of under-five
mortality declining, neonatal deaths now account for
44 % of all under-five deaths making them a crucial
focus for improving child survival [5–7]. Renewed calls
to action to end these largely preventable child deaths
include addressing gaps in knowledge about stillbirthle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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Day et al. Reproductive Health  (2016) 13:129 Page 2 of 8risk factors and stillbirth prevention as well as prevent-
ing deaths due to birth asphyxia [3, 7, 8].
In recent years, practitioners in low- and middle-
income countries have raised concerns that the use of
uterotonics, an otherwise life-saving treatment, outside
of controlled settings is contributing to these perinatal
deaths [9]. Induction and active management of labor
with uterotonics is a well-established and safe medical
procedure as long as it is conducted in tightly controlled
situations where one can identify correct indications of
risk, precisely administer doses, frequently monitor fetal
heart rate [9, 10] and perform emergency Cesarean sec-
tion when necessary, namely in a CEmONC facility that
follows appropriate procedures. In addition to facilitating
active management of labor and reducing the complica-
tions of prolonged labour, uterotonics are also an im-
portant tool in preventing and treating post-partum
haemorrhage, a leading cause of maternal death in low-
and middle-income countries. Uterotonics can save lives
and manage risk in clinical settings, but they can also
threaten the lives of mothers and babies when used to
augment or induce labor in settings without the appro-
priate resources and adherence to protocols. Such situa-
tions include home birth settings and basic EmONC
facilities without full CEmONC support (henceforth,
“outside uterotonic use”). These outside utertonics are
frequently administered either as a bolus intravenous in-
fusion without strict control of the infusion rate or as
intramuscular injections. Notable consequences of “out-
side uterotonic use” include fetal hypoxia, neonatal
encephalopathy or death, uterine rupture, and maternal
death [9]. However, little systematic evidence has
estimated the relative contribution of outside uterotonic
use to perinatal outcomes [11], and currently none exists
for stillbirth. The perceived benefit to the family of
outside uterotonics use in Bangladesh includes speeding
up labor, shortening labor duration, facilitating delivery,
avoiding hospital delivery and reducing maternal suffer-
ing [12]. Given estimates of home-based uterotonic use
ranging from 10 to 68 % in low- and middle-income
settings [9–13], there have been a number of recent calls
for rigorous studies to quantify the magnitude and effect
of inappropriate augmentation on perinatal and maternal
outcomes [9–12, 14, 15].
This cross-sectional study uses seven years of hospital
records in a low-income setting in rural, northwestern
Bangladesh to estimate the increased risk of several peri-
natal birth outcomes, including stillbirths, from the
reported use of injectable uterotonics to induce or
augment labor outside of CEmONC facilities. We test
the hypothesis that outside uterotonic use will have
negative effects on several, but not all birth outcomes.
Specifically, it should increase the risk of intrapartum
(i.e. “fresh”) stillbirth but not antepartum stillbirths (i.e.“macerated”). It should also increase the risk of early
neonatal death (early NND) especially death caused by
birth asphyxia. We assess this hypothesis against the null
hypothesis of no increased risk among those mothers
administered outside uterotonics.
Methods
Setting
LAMB Hospital is a CEmONC facility serving the rural
poor in Northwest Bangladesh. On average 3500 babies
are delivered at the hospital each year. During the study
period, 5.7 % of all mothers experienced prolonged labor,
3.1 % breech deliveries, and 1.6 % eclampsia. Approxi-
mately one fifth (21.7 %) were treated with Cesarians.
The median birthweight was 2.8 kg (1st quartile = 2.5 kg,
3rd quartile = 3.1 kg). The hospital has developed and
trained medical providers in the use of a simple inter-
active checklist medical record system “circle sheets” for
documenting key maternal and neonatal clinical infor-
mation before, during and after delivery including
history, examination, and diagnoses. In addition to facili-
tating real-time medical decision-making, the circle
sheets are then entered into a customised database,
checked and cleaned for use in standard reporting and
clinical audits. For variables considered here, circle
sheets with fixed responses require the practitioner to
specify at least one response (e.g. Yes, No, or Unknown),
and missing data are relatively rare. All data analyses
here are generated by an ongoing hospital data system
that was originally developed in 2006 along with a
number of quality monitoring, feedback and training
practices aimed at improving completeness and accuracy
of data by midwives and clinicians. These include cross-
comparing data entry, regular checks on completeness
of data, on-ward observations of form completion, and
regular retraining personnel It also involves frequent
data reports to hospital staff and communication with
staff about any changes in the understanding or comple-
tion of the interactive checklist records.
Sample
There were 24935 babies delivered at LAMB Hospital
between January 1st, 2009 and December 31st, 2015. For
these analyses, we exclude twins and triplets (2 · 9 % of
births, n = 724) as well as babies with birthweights
<1000 g (1 · 1 % of births, n = 264) and without informa-
tion on gestational age (n = 19) (Total excluded n = 949).
Pre-term births have a higher risk of adverse outcomes
from prematurity related causes. Thus, we analyse pre-
term births (≤36 week) separately (6 · 3 % of total births,
n = 1560) and present these analyses in the additional
information (see Additional file 1: Table S1). Pre-term
births were classified as ≤36 week gestation using a vali-
dated method based on 8 external characteristics [16].
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births ≥37 weeks and ≥1000 g. Of these 22426 births,
2177 (9 · 7 %) were admitted infants whose guardians
discharged them without doctor’s approval, and thus
were not available for follow-up in the case of complica-
tions. Analyses excluding these early discharged new-
borns (n = 20249) are not substantially different from
those with the full sample (see Additional file 1: Table
S2 for results on this subsample). We report results for
the full sample of 22426 singleton term births in the
main body. The flow diagram in Fig. 1 summarizes the
excluded babies and the analysis pathways.
Variables
Birth outcomes We examined five birth outcomes prior
to discharge: (1) fresh stillbirth, (2) macerated stillbirth,
(3) early neonatal death (before discharge), (4) early neo-
natal death due to intrapartum-related complications
(birth asphyxia), as well as a (5) composite outcome of
perinatal death (stillbirth and early neonatal death).
Stillbirth type (fresh or macerated) was determined by
the midwife or doctor who delivered the baby and re-
corded in the mother’s chart and perinatal death form at
the time of birth. Live born babies were either admitted
to routine postnatal care by midwives or admitted under
pediatric doctors according to strict clinical criteria in-
cluding: sepsis risk, less than 2 kg birth weight, specific
maternal risk factors, growth restriction, significant jaun-
dice, congenital abnormalities, respiratory distress,
weight loss >10 %, resuscitation needed after birth, and
feeding difficulties among other indications. Infants that
died immediately after birth were assessed and the causeFig. 1 Sampling flow diagramof death documented. The 67 % of infants admitted to
the hospital for routine postnatal care by midwives were
determined free of these problems after a postnatal
check. Each of the 33 % of infants admitted to the hos-
pital under pediatric doctors was classified as either alive
at discharge or early neonatal death (death within 7 days
of delivery prior to discharge). Admitted babies length of
stay was median 2 · 0 days and mean 2.5 days. For all
early neonatal deaths, a senior obstetrician and senior
pediatrician reviewed the mother and baby’s case notes
as part of a monthly perinatal death audit. Causes of
death were coded by these senior clinicians with the
“Perinatal Problem Identification Programme (PPIP)”,
originally designed and developed in South Africa as a
facility audit tool for perinatal deaths [17]. The PPIP has
5 subcodes for hypoxia (hypoxia, hypoxic ischemic en-
cephalopathy, meconium aspiration, persistent fetal cir-
culation and hypoxia other) which we attribute to
intrapartum-related complications (birth asphyxia). All
data was extracted from the hospital database, Flow In-
formation System Hospital or FISH [18].
Reported outside uterotonic use At admission to the
CEmONC unit, all mothers were routinely asked by the
admitting midwife or doctor whether intramuscular
injections or drips had already been administered to
increase labor pains before arrival at this hospital.
Mothers come to this CEmONC either from home or
local basic EmONC facilities and only rarely are they
given referral papers with details of treatment adminis-
tered. Injectable uterotonics such as oxytocin are widely
available in Bangladesh and use outside the CEmONC is
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ous infusion or drip without any monitoring [12]. If
mothers stated they had received injections or drip prior
to coming to the hospital, either affirmatively or in terms
of the number of treatments, this was documented on
their clinical records and subsequently entered into the
database coded as 1 for “outside uterotonic use”. Other-
wise they were coded as 0. It was not documented
whether the outside injectable uterotonic use had been
in the home or at a Basic EmONC facility. Nor was the
provider of the outside uterotonic documented eg the
Village Doctor - a type of unqualified allopathic provider
who usually operates in the home setting [12] or a
medically trained provider in the basic EmONC setting.
Covariates We considered five potential covariates—pro-
longed labor, pre-eclampsia, eclampsia, induction or aug-
mentation by uterotonics in the CEmONC hospital
setting (LAMB Hospital), and Cesarian section.
Prolonged labor is a potential confounder of any
observed relationship between outside uterotonic use
and birth outcomes as prolonged labor can both: (1) lead
caregivers to seek uterotonics in the home or in
non-comprehensive EmONC facilities and (2) precipitate
birth complications including intrapartum-related
neonatal complications (birth asphyxia). For approxi-
mately 90 % of births, health workers documented infor-
mation on when the mother’s first stage of labor had
begun. This information was from mother’s self-report if
she presented at the hospital already in the first stage of
labor or from the partograph if her first stage started
after admission. The duration of labor was calculated by
subtracting the beginning of first stage labor from the
time of delivery. A categorical prolonged labor variable
was created with labor <12 h = 1, labor 12–24 h = 2,
labor >24 h = 3, and labor time is missing = 4.
Eclampsia and pre-eclampsia are additional complica-
tions that may be confounding variables between outside
uterotonic use and deaths due to birth asphyxia. Thus,
we control for the effect of two levels of pre-eclampsia
(moderate and severe) and eclampsia diagnosed by a
clinical checklist. In this context, both CEmONC facility
uterotonics to induce or augment and Cesarian section
may arise from prolonged labor which could both
precipitate outside uterotonic use prior to arrival at the
EmONC facility and increase the risk of perinatal
mortality. Thus we include these two procedures as
proxies for potential confounders. Uterotonic induction
or augmentation in LAMB Hospital is initiated by an
Obstetric doctor for inadequate progress on the parto-
graph. Uterotonic induction or augmentation at LAMB
Hospital is documented in the maternal notes and
entered on the database as a categorical variable: Yes,
No or Unknown. Intermittent fetal heart monitoring isperformed every 15 min for labors being induced or aug-
mented with uterotonics. Cesarian section was recorded
in the maternal birth chart and entered on the database
as 1 = Cesarian section and 0 = no Cesarian section.
Analysis
We report raw rates of five outcomes—fresh stillbirth,
macerated stillbirth, early neonatal death (before
discharge), deaths due to birth asphyxia, and a fifth com-
posite outcome of total perinatal deaths—for both the
entire sample and the sub-sample reporting uterotonic
use outside of CEmONC. We use a logistic regression to
estimate the effect of outside uterotonic use on these
outcomes, reporting both a crude, unadjusted odds
ratios and odds ratios adjusted for potential covariates—
prolonged labor, pre-eclampsia, eclampsia, uterotonic
administration at the hospital, and Cesarian section.
There were no cases of macerated stillbirth when a
mother experienced eclampsia, so that variable was not
included in the final macerated stillbirth model. Analyses
were conducted in SPSS 22 · 0.
We estimated the population attributable risk percent
from outside uterotonics using formula 4 in Rockhill
and Newman applied to the adjusted relative risk [19].
Specifically, we calculate the population attributable risk
percent pd RR−1RR
 
where pd is the proportion of cases
exposed to the risk factor and RR is the risk ratio associ-
ated with that exposure. The prevalence of all outcomes
is less than 5 % in the population. Thus, we use adjusted
odds ratios as approximations for adjusted relative risks
in this calculation.
Results
Descriptives
Table 1 describes key outcomes and predictors for: (1)
all singleton term births and (2) the sub-group of deliv-
eries where outside uterotonic use was reported.
Prevalence of outside uterotonic use
5 · 6 % of the women reported using an outside utero-
tonic, either as an injection or drip prior to arriving at
the CEmONC facility. Prolonged labor greatly increased
the reported use of uterotonics. For labors reported as
lasting less than 12 h, 5 · 1 % of women reported using
outside uterotonics (3 · 4 % injections and 4 · 4 % drip).
For prolonged labors reported as lasting at least 12 h,
these proportions rose substantially: 14 · 7 % reporting
an outside uterotonic, 11 · 6 % reporting injections
specifically, 13 · 0 % reporting a drip specifically.
Association of outside uterotonic use with birth outcomes
The crude odds ratios for the association of uterotonic
use outside CEmONC with 3 of the 4 birth outcomes
Table 1 Description of singleton term births
All Singleton term births ≥37 weeks
n = 22426
Group reporting outside uterotonics
n = 1260
Perinatal Deaths
Fresh Still Births 361 (1 · 6 %) 63 (5 · 0 %)
Macerated Still Births 191 (0 · 9 %) 8 (0 · 6 %)
Unspecified Still Births 5 (0 · 0 %) 3 (0 · 2 %)
Total early Neonatal deaths 318 (1 · 4 %) 53 (4 · 2 %)
Neonatal deaths from Birth Asphyxia 229 (1 · 0 %) 41 (3 · 3 %)
Total Perinatal deaths 875 (3 · 9 %) 124 (9 · 8 %)
Birth Complications
Prolonged labor (>12 h) 1289 (5 · 7 %) 185 (14 · 4 %)
Pre-eclampsia (Moderate) 63 (0 · 3 %) 5 (0 · 4 %)
Pre-eclampsia (Severe) 303 (1 · 4 %) 12 (1 · 0 %)
Eclampsia 261 (1 · 2 %) 13 (1 · 0 %)
Hospital Procedures
Cesarian-sections 4953 (21 · 1 %) 484 (38 · 4 %)
Cesarians due to fetal compromise 1501 (6 · 7 %) 97 (7 · 7 %)
Uterotonic to augment or induce 7516 (33 · 5 %) 435 (34 · 5 %)
% of births in parentheses
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birth OR = 3 · 8 95 % CI (2 · 8, 4 · 9), early NND OR= 2 · 9
(2 · 1,3 · 9), early NND due to Birth Asphyxia OR = 3 · 8
(2 · 7,5 · 3) (all p < 0.001). These are the birth outcomes
that specifically relate to intrapartum events. The odds ra-
tio for the remaining birth outcome, macerated stillbirth,
which relates to the baby dying before the onset of labor
was not found to be statistically associated with outside
uterotonic use OR = 0 · 7 (0 · 4,1 · 5) (p > 0.10). The crude
odds ratio for the composite birth outcome perinatal
death was substantial and statistically significant OR = 3 · 0
(2 · 4,3 · 6) (p < 0.001) (Table 2).
Table 3 presents the model-adjusted odds ratios. After
controlling for all covariates, there is an increased risk of
all categories of perinatal mortality if the mother had a
diagnosis of either prolonged labor, moderate or severe
pre-eclampsia, and eclampsia. There was no significant
associated between LAMB Hospital administered utero-
tonics and any perinatal outcomes. There was a decreasedTable 2 Crude odds ratios for four perinatal outcomes and total
perinatal mortality
Odds Ratio (95 % CI)
Fresh Stillbirth 3 · 7* (2 · 8,4 · 9)
Macerated Stillbirth 0 · 7 (0 · 4,1 · 5)
Early NND 2 · 9* (2 · 1,3 · 9)
Early NND due to Birth Asphyxia 3 · 8* (2 · 7,5 · 3)
All Perinatal Death (Composite) 3 · 0* (2 · 4,3 · 6)
Notes: *p < 0.001risk of fresh stillbirth and an increased risk of early neonatal
death and death due to birth asphyxia with Cesarian sec-
tions. Overall, Cesarian sections were associated with lower
risk of perinatal mortality (OR = 0.7 (0.5,0.8) (p < 0.001).
When adjusting for prolonged labor, pre-eclampsia,
eclampsia, hospital administration of uterotonics, and
Cesarian section, the associations of all perinatal mortal-
ity outcomes with outside uterotonic use remained sig-
nificant and substantial, with the exception of macerated
stillbirths (Table 3).Estimating population attributable risk
If these statistical associations reflect the causal impact
of outside uterotonic use on perinatal mortality with no
unmeasured confounding or omitted variables, then the
estimated percentage of deaths due to exposure to
uterotonics outside the CEmONC setting is 10 % of
early neonatal deaths, 11 % of birth asphyxia deaths,
10 % of perinatal deaths and 14 % of fresh stillbirths.
These estimates are based on the current population
with a relatively low rate of reported outside uterotonic
use (5.6 %) compared to other published studies. If we
adjust these estimates for higher rates of outside
uterotonic use in other studies (10–68 % of home births)
[9–13], then such uterotonic use would be associated
with much greater percentage of all perinatal mortali-
ty—for example 28 % of perinatal deaths at 20 % births
with outside uterotonic use or 36 % of perinatal deaths
at 30 % outside uterotonic use.
Table 3 Logistic Regressions predicting five birth outcomes from reported outside uterotonics, adjusted odds ratios (singleton, term
births ≥ 37 weeks, n = 22426)
Outcome
Predictor Fresh Stillbirth Macerated Stillbirth Early Neonatal Death Intrapartum causes (Birth Asphyxia) All Perinatal Deaths
Outside uterotonics 4 · 0*** (3 · 0,5 · 3) 0 · 8 (0 · 4,1 · 7) 2 · 9*** (2 · 1,4 · 0) 3 · 1** (2 · 2,4 · 5) 3 · 0*** (2 · 4,3 · 7)
Labor duration
<12 h ref. ref. ref. ref. ref.
12–24 h 3 · 1*** (2 · 1,4 · 4) 1 · 9* (1 · 0,3 · 5) 1 · 9** (1 · 3,2 · 9) 2 · 1** (1 · 3,3 · 3) 2 · 5*** (1.9,3.2)
>24 h 2 · 5*** (1 · 5,4 · 3) 1 · 7 (0 · 7,3 · 8) 1 · 0 (0 · 4,2 · 3) 1 · 1 (0 · 5,2 · 8) 1 · 8** (1 · 2,2 · 6)
Missing 2 · 4*** (1 · 5,3 · 9) 2 · 6* (1 · 1,6 · 0) 1 · 3 (0 · 9,1 · 9) 1 · 2 (0 · 8,1 · 9) 1 · 7*** (1 · 3,2 · 3)
Pre-eclampsia
none ref. ref. ref. ref. ref.
moderate 2 · 0 (0.5,8.4) 1 · 7 (0.2,12.2) 2 · 0 (0.5,8.2) 2 · 8 (0.7,11.5) 2 · 0 (0.8,5.0)
severe 4 · 5*** (2.7,7.6) 3 · 0** (1.5,6.3) 2 · 6** (1.4,4.7) 3 · 3*** (1.8,6.2) 3 · 6*** (2.5,5.1)
Eclampsia 4 · 7*** (2.8,7.9) NA 4 · 7*** (2.8,7.8) 5 · 6*** (3.2,9.7) 3 · 7** (2.5,5.4)
Hospital-based Uterotonic Augmentation
No ref. ref. ref. ref. ref.
Yes 1 · 0 (0 · 5,1 · 9) 2 · 4 (0 · 5,10 · 9) 0 · 6 (0 · 4,1 · 1) 0 · 7 (0 · 3,1 · 4) 0 · 8 (0 · 5,1 · 3)
Unknown 1 · 2 (0 · 6,2 · 5) 5 · 8* (1 · 3,27 · 0) 0 · 8 (0 · 5,1 · 5) 1 · 1 (0 · 5,2 · 3) 1 · 3 (0 · 8,2 · 0)
Cesarian Section
No ref. ref. ref. ref. ref.
Yes 0 · 3*** (0 · 2,0 · 4) 0 · 1*** (0 · 0,0 · 2) 2 · 0*** (1 · 6,2 · 6) 2 · 1*** (1 · 6,2 · 8) 0 · 7*** (0 · 5,0 · 8)
Adjusted Odds Ratio with 95 % CI in parentheses, adjusted for length of labor, hospital-based uterotonic augmentation or induction, pre-eclampsia, eclampsia,
and Cesarian section
Note: ref reference category
***p < 0.001, **p < 0.01, *p < 0.05
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In a CEmONC setting in Northwestern Bangladesh, we
find that reported uterotonic use prior to arrival is associ-
ated with a substantially increased risk of perinatal mortal-
ity, including fresh stillbirth, early neonatal death prior to
discharge, and death from birth asphyxia. This effect is
independent of the potential confounding effect of
prolonged labor, pre-eclampsia, eclampsia, CEmONC-
administration of uterotonics and Cesarian section.
Consistent with the expectation that outside uterotonic
use increases the risk for perinatal mortality, there is no
association with macerated stillbirth which would in most
cases result from antepartum fetal death that precedes
uterotonic use in labour. The findings about neonatal
outcomes confirm results of a recent study in another
South Asian setting showing similar relationships between
unmonitored uterotonic use and neonatal mortality and
morbidity [11]. However, by estimating the increased risk
of fresh stillbirth associated with outside uterotonic use,
our findings also highlight the potential impact of utero-
tonic use outside of CEmONC on all babies’ lives during
the entire continuum of intrapartum and postnatal life.
In this setting, we estimate that outside uterotonic use
accounts for 10 % of all perinatal deaths, including 11 %
of birth asphyxia deaths and 14 % of fresh still births.However, in both hospital- and community-based
surveys conducted in the hospital catchment area, this
population has substantially lower rates of reported
outside uterotonic use than other populations in South
Asia and low-income countries (5 · 6 % and 2.3 to 23.5 %
in representative surveys of recent births in the hospital
source communities compared to 10–68 % in other
studies) [9–13]. If we assume outside uterotonic use is
associated with the same risk of perinatal mortality as in
a setting with higher rates of home-based births use
uterotonics, then we estimate much higher proportions
of perinatal deaths would be due to uterotonics outside
a facility with appropriate controls in place (e.g., 28 % of
perinatal deaths with 20 % use).
Although this study showed no evidence of increased
risk from uterotonics administered after arrival at this
CEmONC facility, it is important to point out that deliv-
ery in a facility designated as CEmONC may not be
synonomous with appropriate control. Specifically, it is
crucial to have controls in place for appropriate
monitoring and regulation of the uterotonic infusion
including, monitoring uterine contractions, fetal heart-
rate, use of the partograph as a decision making tool and
immediate access to Cesarian section when needed . Not
all CEmONC facilities may adhere to these standards in
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CEmONC facility with the capacity to provide a
Cesarian-section within 20 min of admission, as is the
case in this study, there are still a remarkable number of
perinatal deaths which may be due to the sequelae of
prior outside uterotonic use.
These findings must be interpreted in light of a number
of data limitations. Reporting in locally meaningful lan-
guage of “injections and drips to increase labor pains” is
only a proxy for actual use of uterotonics outside the
CEmONC facility. It is likely subject to underreporting to
hospital staff due to either self-presentation bias on the
part of patients or failure to ask and / or document on the
part of staff. It is possible that some of the drips adminis-
tered outside were plain intravenous fluids and did not
contain uterotonics. Nonetheless, the proxy measure for
uterotonic use is strongly associated in the expected direc-
tion with perinatal outcomes, suggesting that it is a suit-
ably valid measure of outside uterotonic use. Assessing
the stage in labour that the mother presented to the
CEmONC hospital and at which stage the outside jnject-
able uterotonics were used as well as the dose or
frequency used were beyond the scope of this study.
The deliveries at LAMB hospital also represent a
selective sample of all those deliveries in the surrounding
area [20, 21]. They likely include more complications and
fewer normal deliveries than occur in the surrounding
population, and thus leave open questions about the
generalizability of the specific estimates or qualitative find-
ings to the broader population. Recent efforts to monitor
outside uterotonic use and perinatal mortality for all deliv-
eries in the hospital’s surrounding area will hopefully shed
new light on the generalizability of these findings.
It is also possible that prolonged labor still confounds
the relationship between outside uterotonic administra-
tion and perinatal mortality, but that error in assessing
prolonged labor leads to incomplete detection of statis-
tical confounding. However, the fact that adding an
assessment of prolonged labor does almost nothing to
change the estimated effect of outside uterotonic use on
perinatal mortality partially alleviates this concern.
Conclusions
We find that reported use of uterotonics prior to arriv-
ing at the comprehensive facility is associated with a
substantially increased risk of perinatal mortality. These
findings point to the potentially substantial improvement
in perinatal mortality to be made by reducing the cur-
rently widespread use of uterotonics for induction and
augmentation outside of CEmONC facilities in low- and
middle-income countries. Such efforts would benefit
from systematic surveillance of such use as well as stud-
ies that identify and target the specific pathways by
which uterotonics come to be administered outside ofCEmONC facilities. These will crucially involve a better
understanding of the way that local availability,
perceived medical need, and family demands for a quick
delivery play a role in guiding decisions to use utero-
tonics outside of CEmONC facilities.
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